Solution-phase fragment condensation of leupeptide active pharmaceutical ingredients remains a commercially relevant route where resin-based assembly generates difficult-to-purify deletion sequences or where C-terminal L-leucyl fragments must be isolated as discrete intermediates. In this segment, L-leucine ethyl ester hydrochloride is introduced as a C-terminal building block after the free amine is liberated with 1.0–1.1 mol eq of N-methylmorpholine in ethyl acetate or dichloromethane at 0–5 °C. The charge ratio against the N-protected amino acid or peptide acid is maintained at 0.95–1.05 mol eq because residual primary amine above 1.10 mol eq promotes diketopiperazine formation during subsequent saponification or hydrogenolysis steps. For coupling, water-soluble carbodiimide is used at 1.0–1.2 mol eq with hydroxybenzotriazole at 1.0–1.2 mol eq in a glass-lined reactor producing batch sizes from 500 L to 5000 L; the jacket is held at −5 °C to +5 °C during activation, then the mass is warmed to 20–25 °C over 6–24 h. When the terminal ethyl ester is retained in the API fragment, the workup includes sequential washes with 5% w/w citric acid, 5% w/w sodium bicarbonate, and brine, followed by vacuum distillation at 35–45 °C and 50–150 mbar; if the free acid is required, saponification with lithium hydroxide at 1.05–1.15 mol eq in tetrahydrofuran/water 3:1 is run at 0–5 °C to reduce racemization. The compliance framework is governed by ICH Q7 Section 7 for incoming material verification and Section 8 for production and in-process controls, while finished peptide API manufacturing falls under 21 CFR 210 and 21 CFR 211; chromatographic purity is assessed following USP <621>, and residual solvent testing follows USP <467>. The terminal finished-product types include C-terminal L-leucyl peptide fragments, protected peptide acids, and therapeutic peptide drug substances with L-leucyl residues used in endocrine, oncologic, and anti-infective candidates. The process boundary is moisture-sensitive: when ambient relative humidity exceeds 60%, the hydrochloride salt is pre-dried at 40 °C under 30–50 mbar for 4–6 h before neutralization, and residual water in the coupling solvent above 0.05% w/w shortens activated-ester half-life. Aqueous alkaline washes above pH 9.0 convert the ester hydrochloride to the free amine, which partitions into the organic phase and causes yield loss if not controlled.

Which Control Limits Govern Fmoc-Leu-OH and Boc-Leu-OH Produced From Ethyl Ester Hydrolysis?

The conversion of L-leucine ethyl ester hydrochloride into N-protected leucine derivatives is not a single-step protection: the ethyl ester must be kept intact during amine protection, then hydrolyzed under conditions that minimize α-carbon racemization. Current contract manufacturing practice first neutralizes the hydrochloride with 1.0–1.1 mol eq of aqueous sodium carbonate or sodium hydroxide at 0–5 °C, then charges di-tert-butyl dicarbonate at 1.05–1.20 mol eq in tetrahydrofuran/water 3:1 for Boc protection. For Fmoc protection, Fmoc chloride is introduced at 1.00–1.10 mol eq with 2.0–2.5 mol eq of sodium carbonate in dioxane/water at 0–10 °C; after extraction, the ethyl ester is hydrolyzed with lithium hydroxide at 1.05–1.15 mol eq at 0–5 °C, followed by acidification to pH 2.5–3.0 with 10% w/w citric acid. Crystallization from methyl tert-butyl ether and n-heptane yields protected L-leucine batches with residual ethyl ester below 0.5% w/w and free L-leucine below 0.5% w/w. The downstream production train uses glass-lined reactors with bottom discharge, centrifugal filtration, and vacuum drying at 40±2 °C; analytical release includes reversed-phase HPLC at 210 nm following Ph. Eur. general chapter 2.2.46, headspace gas chromatography following USP <467>, and chromatographic system suitability following USP <621>. Finished-product classes supplied from this segment are Fmoc-L-leucine, Boc-L-leucine, Cbz-L-leucine, and related N-acyl leucine derivatives used in solid-phase peptide synthesis, fragment condensation, and medicinal chemistry laboratories. The operational boundaries are pH- and temperature-dependent: hydrolysis above 10 °C or above pH 12 increases racemization at the α-carbon, and Fmoc-protected intermediates cannot be exposed to strong bases above 25 °C for extended periods because dibenzofulvene cleavage reduces yield.

Although reduction of L-leucine ethyl ester hydrochloride to L-leucinol is exothermic and consumes additional reducing agent because the hydrochloride releases one equivalent of hydrogen chloride, the route retains industrial value when the target chiral ligand requires the branched primary alcohol at the stereogenic centre. In a stainless-steel or glass-lined reactor, the hydrochloride is dissolved in anhydrous tetrahydrofuran at 1.0–1.5 M, and sodium borohydride is charged at 1.5–2.0 mol eq with iodine at 0.5–1.0 mol eq under nitrogen; the addition is maintained below 10 °C, after which the mass is stirred at 40–50 °C for 6–12 h. The reduction mass is quenched with water, treated with 15% w/w aqueous sodium hydroxide to dissolve borate and alumina solids, filtered over Celite, extracted with dichloromethane, and distilled at 90–110 °C under 20–30 mbar. The resulting L-leucinol is then converted into chiral phosphoramidite ligands, oxazoline-phosphine ligands, and organocatalysts through subsequent reaction with phosphorus trichloride intermediates, oxazoline alcohols, or sulfonyl chlorides. Compliance for this segment includes ICH Q7 Section 5 for process equipment cleaning and maintenance, REACH registration obligations for solvent and ligand intermediates, and site-level ISO 9001:2015 Section 8.5 for production control. The moisture limit in tetrahydrofuran is ≤0.05% w/w; above this level the sodium borohydride-iodine reagent decomposes before complete reduction, producing inconsistent yields. Because the hydrochloride salt consumes one equivalent of reducing agent, either pre-neutralization with triethylamine at 1.0–1.05 mol eq or an additional sodium borohydride charge is required when the material has not been pre-dried.

When Chiral Stationary Phase Selector Chemistry Requires L-Leucine Ethyl Ester Hydrochloride as an Amino Acid Anchor

The utility of L-leucine ethyl ester hydrochloride in Pirkle-type chiral stationary phases depends on its availability as a single enantiomer that can be acylated with dinitrobenzoyl or naphthylacetyl recognition groups before bonding to aminopropyl silica. In preparative HPLC media manufacture, the amine is first liberated with 1.0–1.1 mol eq of triethylamine in dimethylformamide at 0–5 °C, then acylated with 1.0–1.1 mol eq of 3,5-dinitrobenzoyl chloride; the resulting N-acylated ester is hydrolyzed with lithium hydroxide at 1.05–1.15 mol eq and coupled to aminopropyl silica at 1.0–1.2 mol eq relative to surface amine. The target bonding density is 0.5–1.0 μmol/m², because higher densities reduce enantioselectivity by sterically blocking the chiral cleft. The bonded silica is wet-packed into 4.6 mm × 250 mm analytical columns or 100 mm × 250 mm preparative columns and qualified with racemic test probes under USP <621>; column efficiency, asymmetry, and retention repeatability are recorded for each packing lot. Compliance is maintained through ISO 9001:2015 Section 8.5 for production and service provision, while analytical instrument qualification follows laboratory-specific SOPs aligned to ISO 17025. Terminal finished-product types include Pirkle-type chiral stationary phases, analytical chiral HPLC columns, preparative chiral separation media, and racemic drug reference standards for enantiomeric purity method validation. Published data for this specific selector configuration is limited to column vendor method-transfer documentation, so loading density is optimized lot-by-lot with racemic test probes rather than inferred from a universal standard curve. Process boundaries include residual water in dimethylformamide above 0.05% w/w, which hydrolyzes the acyl chloride before silica coupling, and bonding density above 1.0 μmol/m², which causes stationary-phase overload and loss of enantioresolution.